Analysis of Beijing Balance Medical's Renato System Gets NMPA Approval for Valve-in-Valve Therapy - aVenture Research
Insight, China's Pharmaceutical Industry
Beijing Balance Medical's Renato System Gets NMPA Approval for Valve-in-Valve Therapy
China's Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s National Medical Products Administration (NMPA) for its Renato Transcatheter Valve-in-Valve System. This is the world's first globally commercialized interventional device based on valve-in-valve (ViV) therapy, targeting high-surgical-risk patients with failed bioprosthetic valve implants. The system addresses conditions such as structural valve deterioration (SVD), prosthesis-patient
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.